Genetics prevail

Prevail Therapeutics Inc.’s focus on genetic subpopulations of patients with neurodegenerative diseases led EcoR1 Capital to join the newco’s tranched $75 million series A round.

The round’s investors included OrbiMed Advisors, Pontifax Fund, RA Capital Management, EcoR1, Omega Funds, BVF Partners, Boxer Capital, Adage Capital Management and Alexandria Venture Investments. Details regarding the tranches were not disclosed...